Atlas Trials

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

Clinical trial NCT04774926 · COMPLETED

Trial details

NCT number
NCT04774926
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Neovascular Age-related Macular Degeneration
Start date
2021-10-15
Primary completion
2023-10-04
Enrollment
122

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.